Where Are We Now? Updates on a Prospective Multi-Center Study of over 400 Dogs with Hemangiosarcoma (ePUSH)

Presentation Description / Summary: The mission of Ethos Discovery, a non-profit incubator of scientific innovation, is to improve outcomes in human and veterinary patients with complex medical problems. To advance this mission, one of Discovery’s first priorities is to deliver curative outcomes to dogs with hemangiosarcoma. The interest in addressing this unmet need has been strongly endorsed by all disciplines of veterinarians charged with identifying unmet needs like this for Ethos Discovery to tackle, including primary care and emergency doctors, cardiologists, radiologists, criticalists, surgeons, and oncologists. The Ethos Precision Medicine Umbrella Study for Hemangiosarcoma (PUSH) is a 5-year, nationwide, prospective, randomized study of over 400 dogs with hemangiosarcoma that links patient-forward correlative clinical research and laboratory efforts focused on comparative tumor biology, genomics and epigenomics. The goals of our comprehensive ongoing Ethos Discovery Hemangiosarcoma Research Program are to address the gaps related to our understanding of the molecular etiopathogenesis, diagnosis, monitoring, and treatment of this devastating cancer in dogs, and more broadly includes: (1) creating translational knowledge from genomic and epigenomic correlative research, (2) blood-based tests (liquid biopsy) to assess burden of disease and disease monitoring, and (3) accelerating drug development in the context of rigorous prospective clinical trials. In this presentation we will share our progress and review preliminary findings from the high-level evidence including updates on therapeutic interventions and novel therapeutic approaches from the Ethos-PUSH clinical trial which suggests that there is more hope for patients than we have been led to believe.

Learner Outcomes: 1. Understand that hemangiosarcoma is not a single disease and outcomes may be stratified by clinical and genomic data. 2. Recognize that new targeted therapies may provide some additional hope for patients with HSA, 3. Learn the genomic landscape is complicated, suggesting various drivers that may represent novel therapeutic targets.